Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 152

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 152
---

as a director of Alphatec Holdings, Inc. (Nasdaq: ATEC), or Alphatec, since July 2024. Prior to his time as a director of Alphatec, Mr.
Valentine served as special advisor to their board of directors from October 2023 until his election in 2024. Mr. Valentine previously
served on the board of directors of SI-Bone, Inc (Nasdaq: SIBN), a developer of minimally invasive surgical treatments for sacroiliac
joint disorders and sacral fixation for spine surgery, from 2015 until 2024. Mr. Valentine holds a B.B.A. degree in Management and Biomedical
Sciences from Western Michigan University.

Mr. Efraim Cohen-Arazi, Director Nominee

Mr. Efraim Cohen-Araziwill become our director at the effective time of the registration statement to which this prospectus relates. Mr. Cohen-Arazi was the Co-Founder & Chief Executive Officer of Rainbow Medical, a leading Israeli medical device innovation house since 2008. From 2004 to 2006 Mr. Cohen-Arazi served as the Chief Executive Officer and Co-Founder of IntecPharma Ltd. and as Chairman of CollPlant Ltd. since 2006. Mr. Cohen-Arazi served as a director in numerous biotech/medtech companies since 2005, and currently serves as a director in PainReform Ltd. (Nasdaq: PRFX). Mr. Cohen-Arazi was the Senior VP Head of Operations at Immunex Corporation in Seattle, Washington until 2002 when it was acquired by Amgen, where he served as VP and General Manager of the TO site in California. Mr. Cohen Arazi served at Merck-Serono Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen-Arazi received a M.Sc. degree from the Hebrew University of Jerusalem, Israel.

<div align='center'>92</div>

Mr. Pini Ben-Elazar, Director Nominee

Mr. Ben-Elazar will become
our director at the effective time of the registration statement to which this prospectus relates, and will serve as an External Director
under the Companies Law for a 3-year term. Mr. ben-Elazar is a very experienced executive as a Chief Executive Officer and as a director
with over 25 years of successful experience in the healthcare industry.